Intersect Capital’s Definium Therapeutics DFTX Stock Holding History

Intersect Capital’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,167	Closed	-$76K	–	447
2021 Q3	$76K	Hold	2,167	–	–	0.01%	402
2021 Q2	$112K	Buy	+2,167	New	+$114K	0.02%	369

Other funds holding DFTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCI

Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Intersect Capital's DFTX Position: Q4 2021 in Review

Intersect Capital sold out of Definium Therapeutics (DFTX) in Q4 2021, closing a stake of 2,167 shares — an estimated $76K sold.

Intersect Capital first reported a position in DFTX in Q2 2021 and held it in 2 quarters. The position peaked at $112K in Q2 2021. 176 funds tracked by Wall St. Rank hold DFTX as of Q4 2021.

Intersect Capital reported no remaining Definium Therapeutics position as of Q4 2021 after selling out during the quarter.
Intersect Capital sold 2,167 Definium Therapeutics shares in Q4 2021, an estimated $76K.
Intersect Capital first reported a position in Definium Therapeutics in Q2 2021 and held it in 2 quarters.
Intersect Capital's Definium Therapeutics position peaked at $112K in Q2 2021.
176 funds tracked by Wall St. Rank held Definium Therapeutics as of Q4 2021.

Based on Intersect Capital's 13F filing for Q4 2021, filed 14 Feb 2022.